Previous Article | Next Article 
Journal of Virology, May 2001, p. 4430-4434, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4430-4434.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Rabies Virus-Based Vectors Expressing Human Immunodeficiency
Virus Type 1 (HIV-1) Envelope Protein Induce a Strong,
Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope
Proteins from Different HIV-1 Isolates
James P.
McGettigan,1,2
Heather D.
Foley,1,2
Igor
M.
Belyakov,3
Jay A.
Berzofsky,3
Roger J.
Pomerantz,1,4,5 and
Matthias J.
Schnell1,4,*
The Dorrance H. Hamilton Laboratories, Center
for Human Virology,1 and Departments of
Biochemistry and Molecular Pharmacology,4
Microbiology and Immunology,2 and
Medicine,5 Jefferson Medical
College, Thomas Jefferson University, Philadelphia, Pennsylvania
19107, and Molecular Immunogenetics and Vaccine Research
Section, Metabolism Branch, National Cancer Institute, Bethesda,
Maryland 208923
Received 22 November 2000/Accepted 26 January 2001
Novel viral vectors that are able to induce both strong and
long-lasting immune responses may be required as effective vaccines for
human immunodeficiency virus type 1 (HIV-1) infection. Our previous
experiments with a replication-competent vaccine strain-based rabies
virus (RV) expressing HIV-1 envelope protein from a laboratory-adapted HIV-1 strain (NL4-3) and a primary HIV-1 isolate (89.6) showed that
RV-based vectors are excellent for B-cell priming. Here we report that
cytotoxic T-lymphocyte (CTL) responses against HIV-1 gp160 are induced
by recombinant RVs. Our results indicated that a single inoculation of
mice with an RV expressing HIV-1 gp160 induced a solid and long-lasting
memory CTL response specific for HIV-1 envelope protein. Moreover, CTLs
from immunized mice were not restricted to the homologous HIV-1
envelope protein and were able to cross-kill target cells expressing
HIV-1 gp160 from heterologous HIV-1 strains. These studies further
suggest promise for RV-based vectors to elicit a persistent immune
response against HIV-1 and their potential utility as efficacious
anti-HIV-1 vaccines.
*
Corresponding author. Mailing address: 1020 Locust
Street, Suite 335, Philadelphia, PA 19107-6799. Phone: (215) 503-1260. Fax: (215) 923-1956. E-mail:
matthias.schnell{at}mail.tju.edu.
Journal of Virology, May 2001, p. 4430-4434, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4430-4434.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhao, L., Toriumi, H., Kuang, Y., Chen, H., Fu, Z. F.
(2009). The Roles of Chemokines in Rabies Virus Infection: Overexpression May Not Always Be Beneficial. J. Virol.
83: 11808-11818
[Abstract]
[Full Text]
-
Pulmanausahakul, R., Li, J., Schnell, M. J., Dietzschold, B.
(2008). The Glycoprotein and the Matrix Protein of Rabies Virus Affect Pathogenicity by Regulating Viral Replication and Facilitating Cell-to-Cell Spread. J. Virol.
82: 2330-2338
[Abstract]
[Full Text]
-
Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L.
(2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol.
80: 10293-10306
[Full Text]
-
Faber, M., Lamirande, E. W., Roberts, A., Rice, A. B., Koprowski, H., Dietzschold, B., Schnell, M. J.
(2005). A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol.
86: 1435-1440
[Abstract]
[Full Text]
-
Koser, M. L., McGettigan, J. P., Tan, G. S., Smith, M. E., Koprowski, H., Dietzschold, B., Schnell, M. J.
(2004). Rabies virus nucleoprotein as a carrier for foreign antigens. Proc. Natl. Acad. Sci. USA
101: 9405-9410
[Abstract]
[Full Text]
-
McKenna, P. M., Pomerantz, R. J., Dietzschold, B., McGettigan, J. P., Schnell, M. J.
(2003). Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes. J. Virol.
77: 12782-12794
[Abstract]
[Full Text]
-
McGettigan, J. P., Naper, K., Orenstein, J., Koser, M., McKenna, P. M., Schnell, M. J.
(2003). Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J. Virol.
77: 10889-10899
[Abstract]
[Full Text]
-
McGettigan, J. P., Pomerantz, R. J., Siler, C. A., McKenna, P. M., Foley, H. D., Dietzschold, B., Schnell, M. J.
(2002). Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic. J. Virol.
77: 237-244
[Abstract]
[Full Text]
-
Novitsky, V., Cao, H., Rybak, N., Gilbert, P., McLane, M. F., Gaolekwe, S., Peter, T., Thior, I., Ndung'u, T., Marlink, R., Lee, T. H., Essex, M.
(2002). Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C. J. Virol.
76: 10155-10168
[Abstract]
[Full Text]
-
Foley, H. D., Otero, M., Orenstein, J. M., Pomerantz, R. J., Schnell, M. J.
(2002). Rhabdovirus-Based Vectors with Human Immunodeficiency Virus Type 1 (HIV-1) Envelopes Display HIV-1-Like Tropism and Target Human Dendritic Cells. J. Virol.
76: 19-31
[Abstract]
[Full Text]
-
McGettigan, J. P., Sarma, S., Orenstein, J. M., Pomerantz, R. J., Schnell, M. J.
(2001). Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector. J. Virol.
75: 8724-8732
[Abstract]
[Full Text]